日报更新时间：04-10 10:00
周报更新时间：04-11 03:39
今开价：212.68
最高价：214.45
成交量：1454781.0
昨收价：213.35
最低价：211.21
最新价：213.6
中文名称：福泰制药
英文名称：Vertex Pharmaceuticals
行业：医疗
简介：Vertex Pharmaceuticals Incorporated成立于1989年,是一家全球性生物技术公司
电话：1-617-3416100
福泰制药公司从事用来治疗绝症的新型小分子药物的发明、开发及销售，临床研发八种新型治疗病毒疾病、炎症、癌症、自动免疫的疾病和神经混乱的药物，是组织药物设计的领导公司。Vertex Pharmaceuticals公司专注于开发及商业化： 囊肿纤维化治疗的疗法； 癌症； 传染性疾病，包括病毒传染，如流感、细菌传染；自体免疫疾病，如风湿性关节炎； 肠道炎症； 神经障碍疾病，包括疼痛、亨丁顿舞蹈症、多发性硬化症。福泰制药公司Vertex Pharmaceuticals(VRTX)商业化产品： Telaprevir (Incivek)——Vertex开发的口服治疗丙型肝炎药物（蛋白酶抑制剂），2011年5月获得FDA批复上市，欧洲市场与Johnson & Johnson合作推广，亚洲市场与Mitsubishi（日本三菱）合作； Ivacaftor (商标名Kalydeco)——被指定为孤儿药，用于治疗囊性纤维化病。2012年1月31日，Vertex获得FDA批准上市，Vertex与囊性纤维化基金会（Cystic Fibrosis Foundation）合作了13年，来研发此药。福泰制药公司Vertex Pharmaceuticals(VRTX)临床阶段产品： VX-661——与Ivacaftor结合使用的校正化合物，目前处于III期开发阶段； VX-371——一种研究上皮钠通道，目前处于II期开发阶段； VX-152和VX-440——CFTR校正化合物，处于I期临床试验； 此外，Vertex制药还有一批肿瘤学、疼痛和神经学等领域的早期和中期研究、发展项目。截止目前，Vertex Pharmaceuticals, Inc.已与Cystic Fibrosis Foundation Therapeutics Incorporated、Parion Sciences, Inc.、CRISPR Therapeutics AG、BioAxone Biosciences, Inc.、Janssen Pharmaceuticals, Inc.建立合作关系。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2018-06-03 | Bhatia (Sangeeta N) | Director | Sell | 875 | 152.05 |
| 2018-05-31 | Young (William D) | Director | Buy | 1801 | -- |
| 2018-05-31 | Sachs (Bruce I) | Director | Buy | 1801 | -- |
| 2018-05-31 | Sachs (Bruce I) | Director | Sell | 2188 | -- |
| 2018-05-31 | McGlynn (Margaret G) | Director | Sell | 2188 | -- |
| 2018-05-31 | McGlynn (Margaret G) | Director | Buy | 1801 | -- |
| 2018-05-31 | Lee (Yuchun) | Director | Buy | 1801 | -- |
| 2018-05-31 | Kearney (Terrence C) | Director | Buy | 1801 | -- |
| 2018-05-31 | Garber (Alan M) | Director | Buy | 1801 | -- |
| 2018-05-31 | Bhatia (Sangeeta N) | Director | Buy | 1801 | -- |
| 2018-05-31 | Ullian (Elaine S) | Director | Buy | 1801 | -- |
| 2018-05-14 | Smith (Ian F) | Chief Operating Officer | Sell | 217 | 155.78 |
| 2018-05-14 | Silva Paul M | Officer | Sell | 201 | 155.78 |
| 2018-05-14 | Sachdev (Amit) | Officer | Sell | 83 | 155.78 |
| 2018-05-14 | Altshuler David | Officer | Sell | 98 | 155.78 |
| 2018-05-14 | Parini (Michael) | Officer | Sell | 85 | 155.78 |
| 2018-05-14 | Arbuckle (Stuart A) | Officer | Sell | 138 | 155.78 |
| 2018-05-10 | Smith (Ian F) | Chief Operating Officer | Sell | 4096 | 155.00 |
| 2018-05-10 | Smith (Ian F) | Chief Operating Officer | Buy | 2155 | 91.05 |
| 2018-05-10 | Smith (Ian F) | Chief Operating Officer | Buy | 1941 | 86.52 |
| 2018-05-02 | Parini (Michael) | Officer | Sell | 2330 | 149.50 |
| 2018-05-02 | Parini (Michael) | Officer | Buy | 2330 | 86.52 |
| 2018-04-25 | Smith (Ian F) | Chief Operating Officer | Buy | 2125 | 96.87 |
| 2018-04-25 | Parini (Michael) | Officer | Sell | 38250 | 159.56 |
| 2018-04-25 | Parini (Michael) | Officer | Buy | 38250 | 122.45 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Geode Capital Management, LLC | 3235497 | 1.26% | -2883115 | -47.12% | 2019-03-31 |
| State Street Corporation | 11484046 | 4.48% | 643769 | 5.94% | 2019-03-31 |
| Capital Research and Management Company | 15187733 | 5.91% | 432015 | 2.93% | 2019-07-31 |
| Fidelity Management & Research Company | 16934789 | 6.59% | -535417 | -3.06% | 2019-07-31 |
| Vanguard Group Inc | 19481561 | 7.61% | 92370 | 0.48% | 2019-03-31 |
| BlackRock Inc | 20176298 | 7.88% | 568488 | 2.90% | 2019-03-31 |
| Fidelity Management and Research Company | 23847322 | 9.31% | 3886479 | 19.47% | 2019-03-31 |
| FMR Inc | 24434159 | 9.54% | 3951050 | 19.29% | 2019-03-31 |
| T. Rowe Price Associates, Inc. | 26146644 | 10.21% | 397233 | 1.54% | 2019-03-31 |
| Capital World Investors | 10913727 | 4.26% | 1033361 | 10.46% | 2019-03-31 |
| Wellington Management Company LLP | 8828785 | 3.45% | 210383 | 2.44% | 2019-03-31 |
| T. Rowe Price | 7617380 | 2.96% | -9589 | -0.13% | 2019-07-31 |
| AllianceBernstein L.P. | 3317232 | 1.30% | 386502 | 13.19% | 2019-03-31 |
| State Street Global Advisors | 4290493 | 1.67% | 7389 | 0.17% | 2019-07-31 |
| Renaissance Technologies Corp | 5078717 | 1.98% | 744417 | 17.18% | 2019-03-31 |
| ClearBridge Advisors, LLC | 5314705 | 2.08% | -168447 | -3.07% | 2019-03-31 |
| Fidelity SelectCo, LLC | 5793470 | 2.25% | 127000 | 2.24% | 2019-07-31 |
| Jennison Associates LLC | 6800436 | 2.66% | -141185 | -2.03% | 2019-03-31 |
| BlackRock Fund Advisors | 7071124 | 2.75% | 25493 | 0.36% | 2019-07-31 |
| Vanguard Investments Australia Ltd | 7166664 | 2.79% | 68109 | 0.96% | 2019-07-31 |
| Amvescap Plc. | 3706217 | 1.45% | -11713 | -0.32% | 2018-12-31 |
| Ameriprise Financial Inc | 4350002 | 1.70% | -1393382 | -24.26% | 2018-12-31 |
| BlackRock Asset Management Canada Ltd | 8007148 | 3.13% | 10578 | 0.13% | 2019-05-31 |
| J.P. Morgan Investment Management, Inc. | 5211737 | 2.04% | 244822 | 4.93% | 2018-09-30 |
| JPMorgan Chase & Co | 7117216 | 2.78% | 355139 | 5.25% | 2018-09-30 |
| Columbia Mgmt Investment Advisers, LLC | 4424532 | 1.73% | -149444 | -3.27% | 2018-09-30 |
| BlackRock Institutional Trust Company NA | 6300738 | 2.47% | -583259 | -8.47% | 2018-06-30 |
| State Street Corp | 10489544 | 4.12% | 455166 | 4.54% | 2018-06-30 |
| J.P. Morgan Investment Management Inc | 4966915 | 1.95% | -976193 | -16.43% | 2018-06-30 |
| Columbia Mangmt Investment Advisers, LLC | 4573976 | 1.79% | 260966 | 6.05% | 2018-06-30 |
| Putnam Investment Management,LLC | 3503520 | 1.37% | 1790926 | 104.57% | 2018-06-30 |
| State Street Global Advisors (Aus) Ltd | 2933277 | 1.15% | 69250 | 2.42% | 2018-09-12 |
| Invesco PowerShares Capital Mgmt LLC | 2863975 | 1.12% | 615965 | 27.40% | 2018-06-30 |
| Northern Trust Investments N A | 2819187 | 1.11% | 9563 | 0.34% | 2018-06-30 |
| Waddell & Reed Investment Management Co | 2228355 | 0.87% | -132591 | -5.62% | 2018-06-30 |
| Goldman Sachs Asset Management LP | 2141886 | 0.84% | 385329 | 21.94% | 2018-06-30 |
| Legg Mason Partners Fund Advisor, LLC | 1986598 | 0.78% | -- | -- | 2018-08-21 |
| Arrowstreet Capital Limited Partnership | 2125216 | 0.83% | 921995 | 76.63% | 2018-03-31 |
| Orbimed Advisors, LLC | 1854600 | 0.73% | 113300 | 6.51% | 2018-03-31 |
| NORGES BANK | 2340504 | 0.92% | 188583 | 8.76% | 2017-12-31 |
| Fred Alger Management Inc | 2018898 | 0.80% | 293215 | 16.99% | 2017-12-31 |
| TIAA-CREF Investment Management LLC | 1891482 | 0.75% | -267106 | -12.37% | 2017-12-31 |
| Vanguard Specialized Funds | 9003258 | 3.56% | -4227083 | -31.95% | 2017-12-31 |
| AQR Capital Management LLC | 1890690 | 0.75% | 1046806 | 124.05% | 2017-09-30 |
| J.P. Morgan Investment Management Inc. | 10647313 | 4.29% | -1983128 | -15.70% | 2016-11-30 |
| UBS Asset Mgmt Americas Inc | 2607131 | 1.05% | -5541 | -0.21% | 2016-09-30 |
| J P Morgan Asset Management (UK) Ltd | 1878982 | 0.76% | -127653 | -6.36% | 2016-09-30 |
| Prudential Financial, Inc. (including investments managed by Jennison Associates LLC) | 13762985 | 3.00% | 1096221755 | 0.10% | 1999-11-30 |
| The Vanguard Group | 15731911 | 3.00% | 1253046711 | 0.10% | 1999-11-30 |
| BlackRock, Inc. | 16383538 | 3.00% | 1304948802 | 0.10% | 1999-11-30 |
| Wellington Management Company, LLP | 16541986 | 3.00% | 1317569185 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Vanguard Growth Index Fund | 1830136 | 0.71% | 63839 | 3.61% | 2019-06-30 |
| SPDR | 2858265 | 1.11% | -7854 | -0.27% | 2019-07-31 |
| T. Rowe Price Growth Stock Fund | 4521575 | 1.76% | -65000 | -1.42% | 2019-06-30 |
| Vanguard 500 Index Fund | 5039865 | 1.96% | 59495 | 1.19% | 2019-06-30 |
| T. Rowe Price Lg-Cap Core Gr Strat-UBS | 5161500 | 2.01% | -86900 | -1.66% | 2019-06-30 |
| T. Rowe Price Blue Chip Growth Fund | 5161500 | 2.01% | -86900 | -1.66% | 2019-06-30 |
| Vanguard Health Care Fund | 5940217 | 2.31% | -141800 | -2.33% | 2019-03-31 |
| Vanguard Total Stock Market Index Fund | 7059438 | 2.75% | 62090 | 0.89% | 2019-06-30 |
| American Funds Growth Fund of Amer | 7465157 | 2.90% | 500000 | 7.18% | 2019-06-30 |
| T. Rowe Price Health Sciences Fund | 2675390 | 1.04% | -17300 | -0.64% | 2019-06-30 |
| American Funds New Perspective Fund | 2499900 | 0.97% | -- | -- | 2019-06-30 |
| iShares Core S&P 500 ETF | 1880870 | 0.73% | -930 | -0.05% | 2019-07-30 |
| Ivy Science and Technology Fund | 2050800 | 0.80% | 119100 | 6.17% | 2019-06-30 |
| Fidelity | 2074036 | 0.81% | 34299 | 1.68% | 2019-06-30 |
| Harbor Capital Appreciation Fund | 2154556 | 0.84% | -121724 | -5.35% | 2019-06-30 |
| American Funds Fundamental Invs | 2236827 | 0.87% | -68000 | -2.95% | 2019-06-30 |
| Invesco QQQ Trust | 2300340 | 0.89% | 2030 | 0.09% | 2019-07-31 |
| Vanguard Institutional Index Fund | 2391423 | 0.93% | -14648 | -0.61% | 2019-06-30 |
| iShares Nasdaq Biotechnology ETF | 2419215 | 0.94% | 25013 | 1.04% | 2019-07-30 |
| iShares Core MSCI Kokusai ETF | 1884465 | 0.74% | 1694 | 0.09% | 2019-05-30 |
| iShares Core S&P 500 ETF (CAD-Hedged) | 1884465 | 0.74% | 1694 | 0.09% | 2019-05-30 |
| iShares Core S&P US Total Market ETF | 1884465 | 0.74% | 1694 | 0.09% | 2019-05-30 |
| iShares S&P 500 ETF | 1863983 | 0.73% | 1863983 | -- | 2019-04-25 |
| iShares MSCI World ETF | 1863983 | 0.73% | -3850 | -0.21% | 2019-04-25 |
| T. Rowe Price Institutional Lrg Cp Gr Fd | 1622857 | 0.63% | -15300 | -0.93% | 2018-12-31 |
| VA CollegeAmerica The Gr Fd of Amer | 6465157 | 2.53% | 1609600 | 33.15% | 2018-12-31 |
| VA CollegeAmerica Fundamental Inv | 3214827 | 1.26% | -107500 | -3.24% | 2018-12-31 |
| VA CollegeAmerica New Perspective Fd | 1799900 | 0.70% | 120000 | 7.14% | 2018-12-31 |
| OH Putnam Fidelity Spartan 500 Index | 1914527 | 0.75% | 55396 | 2.98% | 2019-01-31 |
| AZ InvestEd Ivy Science & Tech Fund | 1998100 | 0.78% | -38100 | -1.87% | 2018-12-31 |
| ClearBridge Aggressive Growth Fund | 1595800 | 0.62% | -125000 | -7.26% | 2018-12-31 |
| American Funds IS | 1990900 | 0.78% | 431700 | 27.69% | 2018-09-30 |
| Vanguard Health Care Inv | 7354517 | 2.89% | -587805 | -7.40% | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 6405404 | 2.51% | 27808 | 0.44% | 2018-07-31 |
| Vanguard 500 Index Inv | 4614982 | 1.81% | 6640 | 0.14% | 2018-07-31 |
| T. Rowe Price Growth Stock | 4405475 | 1.73% | -736100 | -14.32% | 2018-06-30 |
| VA CollegeAmerica Grth Fund of Amer 529F | 3665557 | 1.44% | 583957 | 18.95% | 2018-06-30 |
| VA CollegeAmerica Fundamental Invs 529E | 3609727 | 1.42% | 715400 | 24.72% | 2018-06-30 |
| Vanguard Institutional Index I | 2466220 | 0.97% | 3674 | 0.15% | 2018-07-31 |
| T. Rowe Price Health Sciences | 2516690 | 0.99% | 45700 | 1.85% | 2018-06-30 |
| iShares Nasdaq Biotechnology | 2222676 | 0.84% | -4230 | -0.19% | 2018-09-12 |
| PowerShares QQQ ETF | 2087860 | 0.80% | -8070 | -0.39% | 2018-09-13 |
| T. Rowe Price Blue Chip Growth | 5151400 | 2.02% | -195000 | -3.65% | 2018-06-30 |
| Harbor Capital Appreciation Instl | 1517653 | 0.60% | -737526 | -32.70% | 2018-06-30 |
| American Funds NVIT Growth II | 1559200 | 0.61% | 347800 | 28.71% | 2018-06-30 |
| T. Rowe Price Instl Large Cap Growth | 1733057 | 0.68% | -115900 | -6.27% | 2018-06-30 |
| Fidelity Spartan | 1697473 | 0.66% | 20022 | 1.19% | 2018-07-31 |
| ClearBridge Aggressive Growth A | 1720800 | 0.67% | -- | -- | 2018-07-31 |
| AZ InvestEd Ivy Science & Tech E | 2056300 | 0.81% | -- | -- | 2018-06-30 |
| Vanguard Growth Index Inv | 1795142 | 0.70% | -4842 | -0.27% | 2018-07-31 |
| JPMorgan Large Cap Growth Select | 1569080 | 0.62% | 7800 | 0.50% | 2018-02-28 |
| Health Care Select Sector SPDR | 1313660 | 0.54% | -3641 | -0.28% | 2018-02-01 |
| VA CollegeAmerica New Perspective 529E | 1804000 | 0.71% | -400000 | -18.15% | 2017-09-30 |
| Columbia Select Large Cap Growth Z | 2016590 | 0.81% | -135735 | -6.31% | 2016-12-31 |
| Fidelity® Select Biotechnology Portfolio | 5051023 | 2.10% | -- | -- | 2015-09-30 |
| VA CollegeAmerica Fundamental Investors | 4675000 | 1.90% | -75000 | -1.60% | 2015-09-30 |
| VA CollegeAmerica New Perspective | 3859000 | 1.60% | -- | -- | 2015-09-30 |
| JPMorgan Large Cap Growth | 2808500 | 1.10% | 14800 | 0.50% | 2015-09-30 |
| Columbia Select Large Cap Growth Fund | 2614915 | 1.10% | 251520 | 10.60% | 2015-09-30 |
| American Funds NVIT Growth | 2480000 | 1.00% | -105000 | -4.10% | 2015-09-30 |
| VA CollegeAmerica Growth Fund of America | 8066600 | 3.30% | -321000 | -3.80% | 2015-09-30 |
| SPDR® S&P 500 ETF | 2362420 | 1.00% | 17931 | 0.80% | 2015-11-19 |
| Charles F. Wagner | Currently, Charles F. Wagner occupies the position of Chief Financial Officer & Executive Vice President at Vertex Pharmaceuticals, Inc. He is also on the board of Good Start Genetics, Inc. In the past he held the position of Chief Financial Officer & EVP-Administration at Progress Software Corp., Chief Financial Officer & EVP-Administration at Bruker Corp., Manager of Bain & Co., Inc., Chief Financial Officer & Vice President of EMD Millipore Corp., Chief Financial Officer of Ortho-Clinical Diagnostics, Inc., Chief Financial Officer & Vice President of Millipore AB and Manager of Coopers & Lybrand LLP. Charles F. Wagner received an undergraduate degree from Boston College and an MBA from Harvard Business School. |
|---|---|
| Alan M. Garber | Alan M. Garber is on the board of Vertex Pharmaceuticals, Inc. and Exelixis, Inc. and Co-Chairman of edX, Inc., Principal at US Department of Veterans Affairs (West Virginia), Member of American Academy of Arts & Sciences, Member of Institute of Medicine, Member of Association of American Physicians, Member-Science, Technology & Economic Policy Board at The National Academies of Science, Research Associate at National Bureau of Economic Research, Inc., Member of American Society of Clinical Investigation, Professor at Harvard Medical School, Professor at Harvard T.H. Chan School of Public Health, Professor at Harvard Kennedy School of Government, Professor at Harvard University and Member of National Academy of Medicine of United States. He previously was Chairman-Medicare Evidence Development at Centers for Medicare & Medicaid Services (US), Professor at Stanford Graduate School of Business and Professor at Stanford University. Dr. Garber received a doctorate from Stanford University and an undergraduate degree and a doctorate from Harvard University. |
| Paul M. Silva | Presently, Paul M. Silva occupies the position of SVP, Controller & Principal Accounting Officer at Vertex Pharmaceuticals, Inc. He previously held the position of Vice President-Internal Reporting at Iron Mountain, Inc. and Finance Director-Bioscience Technologies Division at Thermo Electron Corp. He received an undergraduate degree from Assumption College. |
| Jeffrey M. Leiden | Dr. Jeffrey M. Leiden is a Chairman, President & Chief Executive Officer at Vertex Pharmaceuticals, Inc., a Chairman at PathAI, Inc., a Member at American Academy of Arts & Sciences, a Member at American Society of Clinical Investigation, a Member at Association of American Physicians, a Member at Institute of Medicine and a Member at National Academy of Medicine of United States. He is on the Board of Directors at Biotechnology Innovation Organization, Macp Organization, Massachusetts Mutual Life Insurance Co., The Boston Private Industry Council, Inc., The Museum of Fine Arts and Vertex Pharmaceuticals (Canada), Inc. Dr. Leiden was previously employed as an Independent Director by Quest Diagnostics, Inc., a Vice Chairman & Non-Executive Director by Shire Plc, a President & Chief Operating Officer by Abbott Laboratories, a Professor by Harvard Medical School, a Chief Cardiology Officer by The University of Chicago, a Founder by CardioGene Therapeutics, Inc., a Managing Director by Clarus Ventures LLC, a Professor-Biological Sciences by Harvard T.H. Chan School of Public Health, a Chairman by Lycera Corp., a Member by National Heart, Lung & Blood Institute, a President & Chief Operating Officer by Pharmaceutical Products, a Trustee by Ravinia Festival Association, a Non-Executive Director by Shire Acquisition, Inc., a Non-Executive Director by Shire Plc /Old/, a Trustee by The Brigham & Women's Hospital, Inc., a Chairman by TYRX, Inc., and a Chairman by Variation Biotechnologies (US), Inc. He also served on the board at Millennium Pharmaceuticals, Inc., Shire Pharmaceuticals, Inc., Biolex Therapeutics, Inc., Cardiovascular Research Institute, Catabasis Pharmaceuticals, Inc. and TAP Pharmaceutical Products, Inc. He received his undergraduate degree from The University of Chicago and a doctorate degree from The University of Chicago. |
| William D. Young | William D. Young is a businessperson who has been at the helm of 7 different companies and presently occupies the position of Chairman for Annexon, Inc., Chairman of NanoString Technologies, Inc. and Chairman of AGY Therapeutics, Inc. He is also Member of National Academy of Engineering and on the board of 6 other companies. Mr. Young previously occupied the position of Chairman at Biogen, Inc. and Chairman at Biogen Idec New Ventures, Inc. (a subsidiary of Biogen, Inc.), Chairman & Chief Executive Officer of Monogram Biosciences, Inc., Chairman for TYRX, Inc. and Chief Operating Officer of Genentech, Inc. William D. Young received an MBA from Indiana University and an undergraduate degree from Purdue University. |
| Bruce I. Sachs | Mr. Bruce I. Sachs is General Partner at Charles River Ventures, Inc. and Co-Lead Independent Director at Vertex Pharmaceuticals, Inc. He is on the Board of Directors at Vanu, Inc., Vertex Pharmaceuticals, Inc., Cedar Point Communications, Inc., Nantero, Inc., Carrier IQ, Inc., M2Z Networks, Inc., Samplify Systems, Inc., iControl Networks, Inc., Accelerated Cure Project for Multiple Sclerosis, SpiderCloud Wireless, Inc., SimpliVity Corp., DataGravity, Inc., Tonian Systems, Inc., and GreatCall, Inc. Mr. Sachs joined CRV in 1999. Formerly CEO of Xylogics, he led a turnaround and sale to Bay Networks where he served as executive vice president, managing four company acquisitions in a year. After leaving Bay Networks, he became CEO of Stratus Computer, ultimately leading the company to its successful sale to Ascend. Mr. Sachs was previously employed as Executive Vice President & General Manager by Ascend Communications, Inc., Executive Vice President & General Manager by Lucent Technologies, Inc., Chief Executive Officer by Nortel Networks Corp., and a Principal by Bell Laboratories. He also served on the board at BigBand Networks, Inc., Acopia Networks, Inc., Celerica, Inc., Flarion Technologies, Inc., and Parascale, Inc. Mr. Sachs received his undergraduate degree from Bucknell University, a graduate degree from Cornell University, and an MBA from Northeastern University. |
| Elaine S. Ullian | Elaine S. Ullian is on the board of Vertex Pharmaceuticals, Inc. and Thermo Fisher Scientific, Inc. In her past career Ms. Ullian held the position of President & Chief Executive Officer of Faulkner Corp., President & Chief Executive Officer at Brigham & Women's Faulkner Hospital, Inc., President & Chief Executive Officer of Boston Medical Center, Associate Professor at Boston University and Faculty Member at Harvard T.H. Chan School of Public Health. Elaine S. Ullian received an undergraduate degree from Tufts University and a graduate degree from the University of Michigan. |
| Margaret G. McGlynn | Margaret G. McGlynn is Chairman at HCU Network America and on the board of 5 other companies. Ms. McGlynn previously occupied the position of President-Global Vaccines & Anti-Infectives at Merck & Co., Inc., President at US Department of Health & Human Services (DC) and President, Chief Executive Officer & Director at International AIDS Vaccine Initiative, Inc. Margaret G. McGlynn received an MBA and an undergraduate degree from State University of New York at Buffalo. |
| Terrence C. Kearney | Terrence C. Kearney is on the board of Vertex Pharmaceuticals, Inc., Acceleron Pharma, Inc. and Levo Therapeutics, Inc. In his past career he held the position of Treasurer & Vice President of Abbott Laboratories and Chief Operating Officer of Hospira, Inc. Terrence C. Kearney received an undergraduate degree from the University of Illinois and an MBA from the University of Denver. |
| Lloyd A. Carney | Lloyd A. Carney is an American businessperson who has been at the head of 7 different companies. Currently, he is Chairman of Lloyd & Carole Carney Foundation, Inc., Chairman & Chief Executive Officer of ChaSerg Technology Acquisition Corp., Independent Non-Executive Chairman at Nuance Communications, Inc. and Chief Executive Officer for Carney Global Ventures LLC. Mr. Carney is also on the board of Vertex Pharmaceuticals, Inc. and Visa, Inc. He previously occupied the position of Chief Operating Officer & Executive Vice President at Juniper Networks, Inc., President-Core IP & Wireless Internet Division at Nortel Networks Corp. and Executive Vice President at Bay Networks, Inc. (a subsidiary of Nortel Networks Corp.), General Manager-NetCool Division at International Business Machines Corp. and Chairman & Chief Executive Officer for Micromuse, Inc. (a subsidiary of International Business Machines Corp.), Vice President-Customer Support at Wellfleet Communications, Inc., Chief Executive Officer & Director at Brocade Communications Systems LLC and Chief Executive Officer & Director at Xsigo Systems, Inc. He received an undergraduate degree from Wentworth Institute of Technology and a graduate degree from Lesley University. |
| Ian Frederick Smith | Presently, Ian Frederick Smith occupies the position of EVP, Chief Operating & Financial Officer at Vertex Pharmaceuticals, Inc. Mr. Smith is also on the board of Acorda Therapeutics, Inc., Infinity Pharmaceuticals, Inc., Vertex Pharmaceuticals (Europe) Ltd. and Vertex Pharmaceuticals (U.K.) Ltd. and Member of The American Institute of Certified Public Accountants, Member of The Financial Executives Institute and Member of Institute of Chartered Accountants in England & Wales. In his past career Mr. Smith was Partner-Life Science & Technology Practice Group at Ernst & Young LLP. Mr. Smith received an undergraduate degree from Manchester Metropolitan University of. |
| Michael J. LaCascia | Currently, Michael J. LaCascia holds the position of Secretary & Senior Vice President at Vertex Pharmaceuticals, Inc. He is also Co-Chairman-Mergers & Acquisitions Committee at Boston Bar Association and Principal at Boston University School of Law. Mr. LaCascia previously held the position of Partner at Wilmer Cutler Pickering Hale & Dorr LLP. He received a graduate degree from Boston University School of Law and an undergraduate degree from Harvard University. |
| Yuchun Lee | Yuchun Lee founded Unica Corp. and Allego, Inc. Presently, Mr. Lee occupies the position of Executive Chairman at Clarabridge, Inc. and Chief Executive Officer at Allego, Inc. Mr. Lee is also on the board of Vertex Pharmaceuticals, Inc. and Concord Academy and Partner at General Catalyst Partners LLC. In his past career Yuchun Lee was VP-Enterprise Marketing Management Business Unit at International Business Machines Corp. and President & Chief Executive Officer of Unica Corp. (a subsidiary of International Business Machines Corp.), Executive-in-Residence at Summit Partners LP, Principal at MIT Lincoln Laboratory, Senior Consultant at Digital Equipment Corp. and Principal at MIT Media Laboratory. Mr. Lee received a graduate degree and an undergraduate degree from Massachusetts Institute of Technology and an MBA from Babson College. |
| David Matthew Altshuler | Currently, David Matthew Altshuler holds the position of Chief Scientific Officer & EVP-Global Research at Vertex Pharmaceuticals, Inc. He is also on the board of New England Aquarium Corp., Becket-Chimney Corners YMCA and Genomics Plc and Founding Member at Whitehead Institute for Biomedical Research, Member of American Academy of Arts & Sciences, Member of Institute of Medicine, Member of Association of American Physicians, Member of American Society for Clinical Investigation, Member of National Academy of Medicine of United States and Professor at Massachusetts Institute of Technology. Dr. Altshuler previously held the position of Deputy Director, Chief Academic Officer & Member at The Broad Institute, Inc., Advisory Board Member at Mpm Capital LLC, Professor at The General Hospital Corp., Senior Analyst at Nuveen Fund Advisors LLC, Director at American Society of Human Genetics, Principal at The SNP Consortium Ltd. and Professor at Harvard Medical School. David Matthew Altshuler received an undergraduate degree from Massachusetts Institute of Technology, a doctorate from Harvard University and a doctorate from Harvard Medical School. |
| Stephanie Franklin | Currently, Stephanie Franklin is President & Director at HR Leadership Forum and Chief Human Resources Officer & Senior VP at Vertex Pharmaceuticals, Inc. In her past career Ms. Franklin occupied the position of Vice President-Talent & Integrated HR Solutions at Blue Cross Blue Shield of Massachusetts Foundation, Co-Founder-Womens Network at Procter & Gamble Co., Senior Vice President-Global Human Resources at Nuance Communications, Inc., Manager-Human Resources at Softworld, Inc., Vice Chairman-Healthy Childhood Development at United Way of Massachusetts Bay, Inc. and Chairman-Manchester Chapter at March of Dimes Foundation. She received a graduate degree and an undergraduate degree from the University of Western Kentucky. |
| Michael Partridge | Currently, Michael Partridge holds the position of Senior Vice President-Investor Relations at Vertex Pharmaceuticals, Inc. He received an undergraduate degree from the University of Massachusetts. |
| Amit K. Sachdev | Amit K. Sachdev is on the board of Massachusetts Biotechnology Council and Eiger BioPharmaceuticals, Inc. and Chief Regulatory Officer & Executive VP at Vertex Pharmaceuticals, Inc. In his past career Mr. Sachdev held the position of Counsel at US House of Representatives, Deputy Commissioner at US Food & Drug Administration and Executive Vice President-Health at Biotechnology Innovation Organization. He received an undergraduate degree from Carnegie Mellon University and a graduate degree from Emory University School of Law. |
| Sangeeta N. Bhatia | Founder of Hepregen Corp. and Glympse Bio, Inc., Sangeeta N. Bhatia is on the board of Vertex Pharmaceuticals, Inc. and Professor at Massachusetts Institute of Technology. She previously was Member of The Broad Institute, Inc., Member of David H. Koch Institute for Integrative Cancer Research, Member-Medicine Department at The Brigham & Women's Hospital, Inc. and Professor at the University of California San Diego. Sangeeta N. Bhatia received an undergraduate degree from Brown University, a doctorate from Harvard Medical School and a doctorate from Massachusetts Institute of Technology. |
| Stephanie Franklin | Currently, Stephanie Franklin is President & Director at HR Leadership Forum and Chief Human Resources Officer & Senior VP at Vertex Pharmaceuticals, Inc. In her past career Ms. Franklin occupied the position of Vice President-Talent & Integrated HR Solutions at Blue Cross Blue Shield of Massachusetts Foundation, Co-Founder-Womens Network at Procter & Gamble Co., Senior Vice President-Global Human Resources at Nuance Communications, Inc., Manager-Human Resources at Softworld, Inc., Vice Chairman-Healthy Childhood Development at United Way of Massachusetts Bay, Inc. and Chairman-Manchester Chapter at March of Dimes Foundation. She received a graduate degree and an undergraduate degree from the University of Western Kentucky. |
| Stuart A. Arbuckle | Mr. Stuart A. Arbuckle is an Independent Director at ImmunoGen, Inc. and a Chief Commercial Officer & Executive VP at Vertex Pharmaceuticals, Inc. He is on the Board of Directors at Rhythm Pharmaceuticals, Inc., ImmunoGen, Inc., Biotechnology Innovation Organization and Cancer Support Community. Mr. Arbuckle was previously employed as a Vice President & GM-Oncology Business Unit by Amgen, Inc. and a Principal by GlaxoSmithKline Plc. He also served on the board at Cerulean Pharma, Inc. and Wellness Community. He received his undergraduate degree from the University of Leeds. |
| Jeffrey A. Chodakewitz | |
| Thomas Graney | Currently, Thomas Graney is Chief Financial Officer & Senior Vice President of Vertex Pharmaceuticals, Inc. He is also on the board of AC Immune SA. In the past he was Chief Financial Officer & SVP-Corporate Strategy at Ironwood Pharmaceuticals, Inc., Chief Financial Officer & Vice President for Ethicon, Inc. and Chief Financial Officer of Tibotec Pharmaceuticals. Thomas Graney received an undergraduate degree from the University of Delaware and an MBA from The Leonard N Stern School of Business. |
| David Matthew Altshuler | Currently, David Matthew Altshuler holds the position of Chief Scientific Officer & EVP-Global Research at Vertex Pharmaceuticals, Inc. He is also on the board of New England Aquarium Corp., Becket-Chimney Corners YMCA and Genomics Plc and Founding Member at Whitehead Institute for Biomedical Research, Member of American Academy of Arts & Sciences, Member of Institute of Medicine, Member of Association of American Physicians, Member of American Society for Clinical Investigation, Member of National Academy of Medicine of United States and Professor at Massachusetts Institute of Technology. Dr. Altshuler previously held the position of Deputy Director, Chief Academic Officer & Member at The Broad Institute, Inc., Advisory Board Member at Mpm Capital LLC, Professor at The General Hospital Corp., Senior Analyst at Nuveen Fund Advisors LLC, Director at American Society of Human Genetics, Principal at The SNP Consortium Ltd. and Professor at Harvard Medical School. David Matthew Altshuler received an undergraduate degree from Massachusetts Institute of Technology, a doctorate from Harvard University and a doctorate from Harvard Medical School. |
| Michael J. Parini | Currently, Michael J. Parini occupies the position of Chief Legal & Administrative Officer, Executive VP at Vertex Pharmaceuticals, Inc. Mr. Parini is also Member of New York State Bar Association and Member of The District of Columbia Bar. He previously held the position of Attorney at Akin, Gump, Strauss, Hauer & Feld LLP and Senior Vice President & Associate General Counsel at Pfizer Inc. Mr. Parini received an undergraduate degree from Georgetown University and a graduate degree from Georgetown University Law Center. |
| Reshma Kewalramani | Presently, Reshma Kewalramani is Chief Medical Officer & Executive Vice President at Vertex Pharmaceuticals, Inc. In her past career she occupied the position of VP-Global Clinical Development & Nephrology at Amgen, Inc. She received a doctorate from Boston University School of Medicine. |
| Kimberly A. White | Kimberly A. White occupies the position of Chief Communications Officer & Senior VP at Vertex Pharmaceuticals, Inc. She is also Chief Communications Officer at Baxter International, Inc. In her past career she occupied the position of Head-Global Health Sector at Daniel J. Edelman Holdings, Inc. and Co-Managing Director-Global Healthcare at Ogilvy Public Relations Worldwide, Inc. She received an undergraduate degree from Northwestern University. |
| Ludovic Fenaux | Ludovic Fenaux is Senior VP-International Commercial Operations at Vertex Pharmaceuticals, Inc. In his past career Mr. Fenaux was Head-Commercial Virology & Transplant at Bristol-Myers Squibb Co. and Senior Vice President at Bristol Myers Squibb Belgium (a subsidiary of Bristol-Myers Squibb Co.). Mr. Fenaux received a graduate degree from ESSEC Business School. |
| Katharine Jensen | Katharine Jensen is Head-Corporate Social Responsibility at Vertex Pharmaceuticals, Inc. She received an undergraduate degree from Boston College and an MBA from University College Dublin. |
| Andrew Partridge | Presently, Andrew Partridge is Chief Commercial Officer & Executive VP at Centrexion Therapeutics Corp. Mr. Partridge is also Regional Head-North America Commercial at Vertex Pharmaceuticals, Inc. In the past Mr. Partridge occupied the position of Executive Director-Sales & Oncology Business Unit at Amgen, Inc. |
| Damian W. Wilmot | Currently, Damian W. Wilmot occupies the position of Chief Risk & Compliance Officer at Vertex Pharmaceuticals, Inc. He is also on the board of 5 other companies. In his past career Mr. Wilmot occupied the position of Partner at Goodwin Procter LLP, Associate for Seyfarth Shaw LLP and Assistant General Counsel at Sunovion Pharmaceuticals, Inc. Mr. Wilmot received an undergraduate degree from Trinity College and a graduate degree from Suffolk University Law School. |
| Patricia N. Hurter | Patricia N. Hurter is on the board of Synlogic, Inc. and Senior Vice President of Vertex Pharmaceuticals, Inc. She received a doctorate from Massachusetts Institute of Technology, a graduate degree from West Virginia University and an undergraduate degree from the University of KwaZulu-Natal. |
| Pamela Stephenson | Pamela Stephenson is on the board of Zynerba Pharmaceuticals, Inc. and Vice President-Global Market Access & Value at Vertex Pharmaceuticals, Inc. Ms. Stephenson received an undergraduate degree from Brown University and a graduate degree from Boston University School of Public Health. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论